5427results about "Capsule delivery" patented technology

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

The present invention relates to an immunomicrobubble complex and its uses. The immunomicrobubble complex (IMC) according to the present invention comprises microbubbles conjugated with an antibody, wherein the microbubbles have excellent stability and excellent antibody binding strength, and it has been confirmed that when the immunomicrobubble complex is treated with high-intensity focused ultrasound (HIFU), the anti-tumor effect is significantly enhanced and an immune-enhancing effect is exhibited. Therefore, the immunomicrobubble complex according to the present invention is expected to improve the delivery efficiency of the conjugated antibody and can be used for the diagnosis and treatment of cancer, and exhibits various functions in the field of immunotherapy, including a contrast effect, improvement of half-life, improvement of drug delivery, lymphocyte concentrating effect, cancer immunotherapy, and ultrasound-induced immunotherapy.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat neurocognitive disorders (e.g., Alzheimer's disease, Parkinson's disease), ADHD, Epilepsy, Autism, Sleep-wake disorders, Chronic pain, Inflammatory Disorders, IBD, Stroke, ALS, and / or Multiple Sclerosis.

The invention provides a preparation method of mitochondria-targeted antioxidant hybrid vesicles. The preparation method comprises the following steps: S1, preparing and separating adipose-derived stem cell nano-vesicles; s2, preparing a liposome loaded with dihydromyricetin and distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000-triphenylphosphine targeting peptide by an ethanol injection method; and S3, preparing the hybrid nano vesicles loaded with the dihydromyricetin and the distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000-triphenylphosphine targeting peptide. The invention also provides the hybrid vesicles prepared by the method and application of the hybrid vesicles in preparation of refractory diabetes wound treatment drugs. The lipidosome and the adipose-derived stem cell nano-vesicles are hybridized to prepare the hybridized vesicles capable of targeting mitochondria and resisting oxidation, the hybridized vesicles are applied to wound treatment for the first time, the problem of oxidative stress of diabetic wounds is solved, wound healing is accelerated, and a new strategy is provided for optimizing mitochondrial function defects and oxidative stress of the diabetic wounds.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat neurocognitive disorders (e.g., Alzheimer's disease, Parkinson's disease), ADHD, Epilepsy, Autism, Sleep-wake disorders, Chronic pain, Inflammatory Disorders, IBD, Stroke, ALS, and / or Multiple Sclerosis.

A G1T38 human oral dosage regime that provides a (mean AUC(0-24),ss (h*ng / mL)) / (dose (mg)) ratio of less than 5 and / or a (mean AUC(0-24),ss (h*ng / mL)) / (Absolute Neutrophil Count (cells / mm3)) ratio on day 22 of dosing of not greater than 1.25.

The application relates to a compound of formula (I) containing a thiazole ring, an indazol ring and a 6,7-dihydro-5H-pyrrolo[1,2-c]imidazole ring system, to pharmaceutical compositions containing it and its medical use. The compounds are described as selective allosteric inhibitors of T790M / L858R, T790M / L858R / C797S, L858R, L858R / C797S containing EGFR mutants and thus useful for the treatment of cancer, in particular non-small cell lung cancer.

This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.

The invention discloses a medical developing marker and a manufacturing method thereof, and relates to the field of medical instruments, the medical developing marker comprises a closed tube, the outer wall of the closed tube is provided with a bionic barb structure, the bionic barb structure is distributed in a flexible zigzag convex manner, and the bionic barb structure and the closed tube are integrally formed through an injection molding process; a closed cavity is arranged in the closed tube, four developing strips are symmetrically arranged in the tube wall of the closed cavity, the tube wall of the region where the developing strips are located is etched to form a weak band, and a developing material layer and a sustained-release medicine layer are sequentially deposited at the weak band. The developing material layer and the sustained-release drug and / or marked nano-particle layer are alternately deposited to form a functional composite layer, and the functional composite layer can directionally rupture to release the therapeutic drug under the action of implantation pressure. The marker integrates the functions of precise development, tissue anchoring and drug sustained release, is adaptive to multi-mode imaging such as ultrasonic imaging, X-ray imaging, CT imaging, MRI imaging and PET-CT imaging, and has remarkable clinical value in precise positioning treatment of solid tumors such as breast cancer and liver cancer.

The invention relates to a starch-based soft capsule shell and a preparation method thereof. The starch-based soft capsule shell is prepared from the following raw materials in parts by mass: 60 to 70 parts of hydroxypropyl starch, 9 to 20 parts of carrageenan, 5 to 15 parts of diquat, 5 to 15 parts of polylysine, 5 to 10 parts of hydroxypropyl methyl cellulose acetate succinate, 15 to 20 parts of glycerol and 30 to 40 parts of pure water. According to the soft capsule shell, hydroxypropyl starch serves as a base material, gelatin is not added, the conditions of poor weather resistance and fishy smell caused by use of gelatin are avoided, through the synergistic effect of all the components, the defects that a starch-based material is poor in plasticity, fragile and insufficient in mechanical strength are overcome, the structural stability is enhanced through chemical crosslinking, and the mechanical strength is improved; and the mechanical property is improved by virtue of physical compounding, so that the low-temperature resistance, high-temperature resistance and mechanical strength of the capsule skin are improved.

The invention provides an anticoagulant coating for medical instruments, which can be used in the field of regenerative medical instruments. The prepared anticoagulant coating has short-term and long-term anticoagulant performance, and in addition, the thrombin responsive nanoparticles wrapped in the hydrogel coating can selectively release a factor Xa (FXa) inhibitor apixaban according to needs, so that thrombosis is inhibited in the middle stage of implantation. In-vitro and in-vivo experimental evidences show that after the material is implanted for a long time, an organized endodermis can be seen on the surface of the material, and the material has a special antithrombotic characteristic. The dynamic adjusting system has a multi-layer protection mechanism, and a new thought can be provided for designing the surface of a contact blood material adapting to environmental conditions.

The present invention discloses automated soft capsule production equipment and a speed regulation method, relating to the field of food and pharmaceutical equipment manufacturing, and is designed to achieve automated soft capsule production. The automated soft capsule production equipment includes an electronic control system, a liquid infusion system, a gelatin strip conveyor system, and a soft capsule pressing and molding system. The electronic control system is connected to the liquid infusion system, the gelatin strip conveyor system, and the soft capsule pressing and molding system, respectively. The gelatin strip conveyor system includes a thickness sensor for measuring the thickness of the conveyed gelatin strip and transmitting a measurement signal to the electronic control system. The gelatin strip conveyor system also includes an angle sensor assembly for measuring the tightness of the conveyed gelatin strip and transmitting a measurement signal to the electronic control system. The electronic control system receives and processes the measurement signal and transmits a control signal to a motor in the gelatin strip conveyor system to adjust the thickness or tightness of the gelatin strip. The liquid infusion system automatically closes and opens the infusion switch via the electronic control system, and the soft capsule pressing and molding system automatically controls the mold compression or release via the electronic control system.

The present invention relates to ultrasound (US) mediated delivery of therapeutic agents, such as the delivery of a drug, gene, nanoparticle or radioisotope, using a bi-phasic microparticle system comprising gas microbubbles, emulsion microdroplets and clusters thereof. Thus, the present invention relates to a cluster composition and a pharmaceutical composition, and their use for delivery of therapeutic agents and as a contrast agent for ultrasound imaging. It further relates to methods for delivering such therapeutic agents and to the use of said compositions.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.

Various embodiments disclosed relate to polymer-encapsulated drug particles and a drug-releasing coating including the same, as well as drug-coated balloon catheters for treating, preventing, or reducing the recurrence of strictures in body lumens and methods of using the same. A drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body lumen stricture includes an elongated balloon. The balloon catheter includes a coating layer overlying an exterior surface of the balloon. The coating layer includes the polymer-encapsulated drug particles; or a drug-releasing coating including the polymer-encapsulated drug particles; or a therapeutic agent and a first and / or second additive; or a combination thereof.

The present invention relates to N-palmitoyl ethanolamide for the treatment of inflammatory pain in combination with a non-steroidal anti-inflammatory drug, to the use of N-palmitoyl ethanolamide (referred to as palmitoyl ethanolamide or PEA) in combination with a non-steroidal anti-inflammatory drug for the treatment of inflammatory pain. Specifically, the present invention relates to palmitoyl ethanolamide for use in the treatment of inflammatory pain, in particular non-neurological inflammatory pain, in which palmitoyl ethanolamide is administered in combination or in combination with a non-steroidal anti-inflammatory drug as needed, in which the administration is separate, combined or simultaneous.

The invention discloses a self-power-generation stomach residence electronic capsule and application thereof, and belongs to the technical field of medical capsules, the self-power-generation stomach residence electronic capsule structurally comprises a capsule shell, and a self-power-generation stomach residence unit, a drug release unit and a circuit system which are arranged in the capsule shell; the self-generating stomach residence unit structure comprises an anode, a plurality of elastic support arms, a cathode and a fastener, and the fastener fixes the plurality of elastic support arms between the anode and the cathode; the anode and the cathode are subjected to primary battery reaction in a gastric juice environment to generate power; the drug release unit is detachably connected with the self-generating gastric residence unit, the drug release unit comprises a drug cabin and a propelling module, the propelling module comprises an electrolyte, an isolating membrane and a propellant, the isolating membrane plays a role in isolating the electrolyte and the propellant and can be dissolved by the electrolyte under the condition that voltage is applied, and the drug cabin is connected with the drug cabin. After the electrolyte is in contact with the propellant, pushing force is generated to release the medicine in the medicine cabin.

The present disclosure generally relates to a monitoring device (100) for remotely monitoring health of a young livestock animal (10), the device (100) comprising: an elongated body (110) within predefined dimensional limits; and a set of electronic components housed within the elongated body (110), the electronic components comprising: a temperature sensor for measuring body temperature of the young livestock animal (10); a computer processor for processing the measured temperature into temperature data; and a wireless communications component for transmitting the temperature data to a remote computer device (210) for processing to monitor the health of the young livestock animal (10), wherein the predefined dimensional limits of the elongated body (110) enable the monitoring device (100) to be orally administrable into the young livestock animal (10) and to remain inside its stomach (12) without being excreted.

This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.

The invention discloses a preparation method of an oral liver protection composition containing ergothioneine, and relates to the technical field of ergothioneine application. The oral liver protection composition containing the ergothioneine is prepared from the following components in parts by mass: 0.5 to 5 parts of the ergothioneine, 10 to 30 parts of silibinin, 20 to 50 parts of a phospholipid complex, 5 to 15 parts of a liver targeting carrier, 2 to 8 parts of a disintegrating agent, 1 to 5 parts of an adhesive and 2 to 4 parts of an antioxidant. Free radicals are efficiently captured through a polycyclic conjugated pi electron system of the antioxidant, a hydrogen bond network is formed by a heteroatom bridging effect of the antioxidant, a galactose group of the liver targeting carrier and the disintegrating agent, and the stability of the system is synergistically improved; the phospholipid complex is embedded with a hydrophobic drug and a hydrophilic carrier, and the drug is accurately delivered to the liver by combining the specific recognition capability of the liver targeting carrier; the ergothioneine and the silybin form a bidirectional synergistic liver protection mechanism by removing reactive oxygen free radicals and regulating and controlling cell signal channels respectively.

The present invention relates to the use of N-palmitoylethanolamide (known as palmitoylethanolamide or PEA) in combination with a non-steroidal anti-inflammatory drug in the treatment of inflammatory pain. In particular, the present invention is directed to palmitoylethanolamide for use in the treatment of inflammatory pain, in particular non-neuropathic inflammatory pain, where palmitoylethanolamide is administered as needed in association or combination with a non-steroidal anti-inflammatory drug, where said administration is separate, combined, or simultaneous.

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.